Andrew Ashby, MD
Pulmonary Disease · Washington, IANPI 1518028505
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (47.3%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 66.9% of it on its own, with 24 other manufacturers making up the rest. Reporting peaked in 2021 at $2,627 and has fallen 98.7% since, to $33 in 2025.
Across 222 payments — averaging $27.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- GSK$776
- Boehringer Ingelheim$245
- Mylan Specialty L.p.$160
- Sunovion Pharmaceuticals Inc.$108
- Regeneron Healthcare Solutions, Inc.$103
- plus $639 from 19 others
What the payments were for
- Consulting fees$91815%
- Speaking & faculty fees$2,25037%
- Food & beverage$2,90047%
- Education$611%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 50 | $4,099 |
| GSK | 87 | $776 |
| Boehringer Ingelheim | 16 | $245 |
| Mylan Specialty L.p. | 10 | $160 |
| Sunovion Pharmaceuticals Inc. | 10 | $108 |
| Regeneron Healthcare Solutions, Inc. | 6 | $103 |
| Electromed, Inc. | 10 | $88 |
| Harmony Biosciences LLC | 5 | $85 |
| Insmed, Inc. | 3 | $53 |
| Sanofi | 3 | $51 |
| Genentech USA, Inc. | 3 | $44 |
| Resmed Corp | 2 | $40 |
| United Therapeutics Corporation | 2 | $35 |
| Medtronic | 1 | $33 |
| Jazz Pharmaceuticals Inc. | 2 | $33 |
| Merck | 2 | $30 |
| Amgen | 2 | $25 |
| Intuitive Surgical | 1 | $19 |
| Nabriva Therapeutics, PLC | 1 | $19 |
| Advanced Respiratory, Inc | 1 | $16 |
| Bayer | 1 | $15 |
| Philips North America LLC | 1 | $13 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
| Inogen, Inc. | 1 | $13 |
| Circassia Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$1,950
- BREZTRI AEROSPHERE$1,218
How this compares
$6,129 in reported general payments places this provider in the 70th percentile of 110 pulmonary disease providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 828 | $561,268 |
| OfevNintedanib Esylate | 41 | $523,074 |
| Dupixent PenDupilumab | 52 | $211,694 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 219 | $156,681 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 242 | $114,862 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 102 | $48,788 |
| Spiriva RespimatTiotropium Bromide | 64 | $41,184 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 270 | $31,505 |
| Breo ElliptaFluticasone/Vilanterol | 66 | $31,158 |
| DuleraMometasone/Formoterol | 40 | $17,080 |
| SymbicortBudesonide/Formoterol Fumarate | 56 | $14,035 |
| Incruse ElliptaUmeclidinium Bromide | 28 | $9,672 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 24 | $9,329 |
| Varenicline Tartrate | 30 | $6,637 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 232 | $5,971 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $776 | $720,5861,181 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $245 | $618,446218 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $4,099 | $180,045299 claims |
| MerckDulera | $30 | $17,08040 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 110 pulmonary disease providers in Iowa.
Other pulmonary disease in Washington
- Bryan KrajicekCouncil Bluffs$470K
- Sumit MukherjeeCouncil Bluffs$264K
- John SouthardCouncil Bluffs$184K
- Dustin McCannWest Des Moines$67K
- Alejandro ComellasIowa City$54K
- Matthew TrumpWest Des Moines$41K
- Brian WittDavenport$19K
- Shrey VelaniDes Moines$18K
- James MallenWest Des Moines$16K
- Neil HorningDes Moines$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.